Exosome VLP Display Vaccine / Capricor - LARVOL DELTA

Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) - "Exosome Platform for COVID-19: Generated mRNA loaded exosomes with 4 viral proteins expressed by SARS-CoV-2; Generated exosome-based VLPs (virus like particles) with 4 viral antigens expressed on the surface of SARS-CoV-2....Anticipated Events and Targeted Milestones for Second Half of 2020: Plan to initiate Phase II, randomized, double-blind, placebo-controlled study in patients in severe or critical condition with COVID-19, subject to FDA approval."

New P2 trial • Preclinical • Infectious Disease • Novel Coronavirus Disease